Friday, 16 October 2026European Markets

SIPEF, LERØY SEAFOOD GP, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - sipef (sip.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
sipef (sip.br) €53.60 5.58% 9.39%
lerøy seafood gp (lsg.ol) kr46.60 5.35% 3.73%
pernod ricard (ri.pa) €194.80 2.69% 13.84%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sipef (sip.br)

5.58% forward dividend yield and 9.39% return on equity

sipef nv operates as an agro-industrial company. it operates through palm, rubber, tea, and bananas and plants segments. the company offers crude palm oil, palm kernels, and palm kernel oil; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; and bananas and plants from ivory coast. it has operations in indonesia, papua new guinea, ivory coast, singapore, europe, and internationally. the company was incorporated in 1919 and is headquartered in schoten, belgium.

earnings per share

as for profitability, sipef has a trailing twelve months eps of €6.8.

pe ratio

sipef has a trailing twelve months price to earnings ratio of 7.88. meaning, the purchaser of the share is investing €7.88 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.39%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jul 3, 2023, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 5.58%.

revenue growth

year-on-year quarterly revenue growth declined by 12.5%, now sitting on 496.25m for the twelve trailing months.

volatility

sipef's last week, last month's, and last quarter's current intraday variation average was a negative 0.12%, a negative 0.03%, and a positive 1.10%.

sipef's highest amplitude of average volatility was 0.88% (last week), 1.18% (last month), and 1.10% (last quarter).

volume

today's last reported volume for sipef is 519 which is 68.84% below its average volume of 1666.

more news about sipef.

2. lerøy seafood gp (lsg.ol)

5.35% forward dividend yield and 3.73% return on equity

lerøy seafood group asa produces, processes, markets, sells, and distributes seafood products worldwide. it operates in three segments: wildcatch; farming; and value-added processing, sales and distribution. the company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. lerøy seafood group asa markets its products primarily under the norway seafoods, arctic supreme, fjord trout, aurora salmon, fossen, sea eagle, lerøy, and m?r brands to shops, restaurants, canteens, and hotels. the company was founded in 1899 and is headquartered in bergen, norway. lerøy seafood group asa is a subsidiary of austevoll seafood asa.

earnings per share

as for profitability, lerøy seafood gp has a trailing twelve months eps of kr1.02.

pe ratio

lerøy seafood gp has a trailing twelve months price to earnings ratio of 45.69. meaning, the purchaser of the share is investing kr45.69 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.73%.

more news about lerøy seafood gp.

3. pernod ricard (ri.pa)

2.69% forward dividend yield and 13.84% return on equity

pernod ricard sa produces and sells wines and spirits worldwide. the company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 pipers, aberlour, absolut, absolut elyx, altos, ararat, augier, avion, ballantine's, becherovka, beefeater, blenders pride, brancott estate, campo viejo, ceder's, chivas, church road, clan campbell, del maguey, george wyndham, green spot, havana club, imperial, imperial blue, italicus, j.p. wiser's, jacob's creek, jameson, jefferson's, kahlúa, kenwood, ki no bi, lillet, long john, l'orbe, lot no. 40, malfy, malibu, martell, method & madness, midleton very rare, minttu, monkey 47, mumm, olmeca, ostoya, passport scotch, pastis 51, pernod, perrier-jouët, plymouth gin, powers, rabbit hole, ramazzotti, redbreast, ricard, royal salute, royal stag, scapa, seagram's gin, secret speyside, smooth ambler, something special, st hugo, stoneleigh, suze, the glenlivet, tx, wyborowa, and ysios. it also provides non-alcoholic beverages under the brands ceder's, suze tonic 0%, cinzano spritz 0%, pacific, campo viejo sparkling 0%, and jacob's creek unvined. the company was founded in 1805 and is headquartered in paris, france.

earnings per share

as for profitability, pernod ricard has a trailing twelve months eps of €9.31.

pe ratio

pernod ricard has a trailing twelve months price to earnings ratio of 20.92. meaning, the purchaser of the share is investing €20.92 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.84%.

revenue growth

year-on-year quarterly revenue growth grew by 5.9%, now sitting on 12.14b for the twelve trailing months.

more news about pernod ricard.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com